Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 3/20 | 0.88 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.56 |
| ▸ | TLR2 | O60603 | 2/20 | 0.55 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.49 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.49 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.49 |
| ▸ | NAAA | Q02083 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6246208 | 1.00 | PRCP (0.88) | PRCPDPP7TLR2GNAI3GNAO1 | |
| SCHEMBL9044288 | 0.95 | PRCP (0.80) | PRCPDPP7TLR2GNAI3GNAO1 | |
| SCHEMBL8602848 | 0.95 | PRCP (0.80) | PRCPDPP7TLR2GNAI3GNAO1 | |
| SCHEMBL23762418 | 0.95 | PRCP (0.97) | PRCPDPP7TLR2GNAI3GNAO1 | |
| SCHEMBL9232625 | 0.95 | PRCP (0.97) | PRCPDPP7TLR2GNAI3GNAO1 | |
| SCHEMBL11842693 | 0.94 | PRCP (1.00) | PRCPDPP7TLR2GNAI3GNAO1 | |
| SCHEMBL16618490 | 0.94 | PRCP (1.00) | PRCPDPP7TLR2GNAI3GNAO1 | |
| SCHEMBL5898619 | 0.94 | PRCP (1.00) | PRCPDPP7TLR2GNAI3GNAO1 | |
| SCHEMBL9825221 | 0.94 | PRCP (1.00) | PRCPDPP7TLR2GNAI3GNAO1 | |
| Bromide SCHEMBL11430734 | 0.94 | PRCP (0.94) | PRCPDPP7TLR2GNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023023513-A9 | STABILIZATION OF OLIGONUCLEOTIDE AND OLIGONUCLEOTIDE-PROTEIN COMPLEX USING ALKYLATED PHOSPHATE | UNIVERSITY OF MASSACHUSETTS (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023023513-A1 | STABILIZATION OF OLIGONUCLEOTIDE AND OLIGONUCLEOTIDE-PROTEIN COMPLEX USING ALKYLATED PHOSPHATE | UNIVERSITY OF MASSACHUSETTS (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2019013790-A1 | ANTIMICROBIAL COMPOUNDS AND USES THEREOF | CURZA GLOBAL, LLC (US) | 2019-01-17 | — | — | WO | disclosed |
| WO-2019013789-A1 | ANTIMICROBIAL COMPOUNDS | CURZA GLOBAL, LLC (US) | 2019-01-17 | — | — | WO | disclosed |
| US-20090321626-A1 | LASER DESORPTION IONIZATION AND PEPTIDE SEQUENCING ON LASER INDUCED SILICON MICROCOLUMN ARRAYS | THE GEORGE WASHINGTON UNIVERSITY | 2009-12-31 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| US-4636567-A | CNS DISORDERS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1987-01-13 | — | — | US | disclosed |
| US-4610821-A | CENTRAL NERVOUS SYSTEM, THYROTROPIN RELEASING HORMONE | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1986-09-09 | — | — | US | disclosed |
| US-4610984-A | CEREBRAL INSUFFICIENCY | CASSELLA AKTIENGESELLSCHAFT (DE) | 1986-09-09 | — | — | US | disclosed |
| US-4564609-A | NERVOUS SYSTEM DISORDERS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1986-01-14 | — | — | US | disclosed |
| EP-0123977-A1 | Substituted piperazin-1-yl-acetic-acid amides, process for their preparation and their use | CASSELLA Aktiengesellschaft (DE) | 1984-11-07 | — | — | EP | disclosed |
| EP-0123444-A1 | 4-Substituted-2-azetidinone compound, process of producing the compounds, and medicaments containing the compounds | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1984-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | PRCP 69/4885DPP7 267/4885TLR2 4846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.